Clinical Trial

Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2022 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
This clinical study is a prospective, multi-center, non-interventional study designed to investigate the safety and effectiveness of percutaneous LAA appendage closure by using LAmbre™ Left Atrial Appendage Occluder System. 579 patients with valvular AF complicated with previous AF-related embolic events (including ischemic stroke, TIA and systemic embolism) were enrolled at about 20 study sites nationwide. The baseline data, operation process and relevant follow-up information of subjects were recorded at 7 months after operation or before discharge and at 1, 3, 6, 12 and 24 months after operation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-09-20.
Status change: Not Yet Recruiting → Recruiting 2022-12-15
Trial Details
NCT Number NCT04559243
Lead Sponsor Lifetech Scientific (Shenzhen) Co., Ltd.
Conditions Non-valvular Atrial Fibrillation, Embolic Stroke
Enrollment 579 participants
Start Date 2020-11-12
Primary Completion 2025-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2022-12-19